
    
      Patients are randomized 1:1 to receive dalteparin 5,000 anti-Xa units s.c. daily versus
      placebo s.c. daily. The primary outcome is VTE-free survival at 6 months. Progression free
      survival; overall survival, toxicity, and neurocognitive performance are secondary outcome
      measures.
    
  